Pharm Country
Filter News
Found 137,489 articles
-
Biohaven Announces Pricing of $230 Million Public Offering of Common Shares
4/18/2024
Biohaven Ltd. announced the pricing of its underwritten public offering of 5,609,757 of its common shares at a price to the public of $41.00 per share.
-
Metsera Launches to Lead the Next Generation of Medicines for Obesity and Metabolic Diseases
4/18/2024
Metsera, Inc., a clinical-stage biopharmaceutical company accelerating the next generation of medicines for obesity and metabolic diseases, announced its launch today.
-
NEXGEL to Present at the Planet MicroCap Showcase: VEGAS 2024, May 1 & 2, 2024
4/18/2024
NEXGEL, Inc. today announced that Adam Levy, Chief Executive Officer, will be presenting at the Planet MicroCap Showcase: VEGAS 2024, taking place at the Paris Hotel and Casino, Las Vegas, NV on May 1st and 2nd.
-
Windtree Therapeutics Announces Reverse Stock Split - April 18, 2024
4/18/2024
Windtree Therapeutics, Inc. today announced that the Company’s Board of Directors has approved a 1-for-18 reverse stock split of its issued and outstanding common stock, par value of $0.001 per share (the “Reverse Stock Split”).
-
SpringWorks Therapeutics to Report First Quarter 2024 Financial Results Thursday, May 2, 2024
4/18/2024
SpringWorks Therapeutics, Inc. today announced that it will host a live conference call and webcast at 8:30 a.m. E.T. on Thursday, May 2, 2024 to report its first quarter financial results and discuss recent business updates.
-
Teleflex Announces First Quarter 2024 Earnings Conference Call Information
4/18/2024
Teleflex Incorporated (NYSE:TFX) will host a conference call to discuss its first quarter financial results and provide an operational update at 8:00 a.m. Eastern Time on Thursday, May 2, 2024.
-
Arbutus to Report First Quarter 2024 Financial Results and Provide Corporate Update
4/18/2024
Arbutus Biopharma Corporation , today announced that it has scheduled its first quarter 2024 financial results and corporate update for Thursday, May 2, 2024.
-
Tiziana Life Sciences Announces New Quantitative PET Imaging Data on Foralumab at the Annual Meeting of the American Academy of Neurology
4/18/2024
Tiziana Life Sciences, Ltd. today announces a platform presentation titled, “Treatment of PIRA with Nasal Foralumab Dampens Microglial Activation and Stabilizes Clinical Progression in Non-Active Secondary Progressive MS” at the Annual Meeting of the American Academy of Neurology in Denver, Colorado.
-
Henry Schein Supports The ‘Carry The Load’ Memorial May Campaign For Third Consecutive Year
4/18/2024
Henry Schein, Inc. (Nasdaq: HSIC) today announced that for the third consecutive year it is supporting the Carry The Load ® Memorial May campaign, a month-long Memorial Day awareness program providing active ways to connect Americans to the sacrifices made by the U.S. military, veterans.
-
Quantum-Si to Report First Quarter 2024 Financial Results on May 9, 2024
4/18/2024
Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), The Protein Sequencing Company™, today announced that it will report financial results for the first quarter 2024 on Thursday, May 9, 2024.
-
Celularity Abstract “Emerging Technologies for the Management and Protection of Tendon Injuries: Decellularized Placental Biomaterials” Accepted at ORS Tendon Conference 2024
4/18/2024
Celularity Inc. (Nasdaq: CELU) (“Celularity”) today announced that its abstract entitled “Emerging Technologies for the Management and Protection of Tendon Injuries: Decellularized Placental Biomaterials” was accepted by the Orthopedic Research Society (ORS) Tendon Conference, which will be held from May 30 - June 1, 2024 at the Mayo Clinic in Rochester, MN.
-
Integra LifeSciences to Reschedule the First Quarter 2024 Financial Results Conference Call to May 6, 2024
4/18/2024
Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology company, today announced that it has rescheduled the release of the Company’s first quarter 2024 financial results to Monday, May 6, 2024.
-
National Comprehensive Cancer Network Awards Champions for Excellence and Outstanding Contributions in Cancer Care
4/17/2024
The National Comprehensive Cancer Network® is announcing 2024 award recipients that include individuals and groups who have made significant and noteworthy impacts on improving cancer care and supporting NCCN's mission to help all people with cancer to live better lives.
-
BAP Pharma Announces Grand Opening Ceremony for New US Headquarters in Somerset, NJ
4/17/2024
BAP Pharma will welcome guests and dignitaries to the Grand Opening Ceremony of its new headquarters on Randolph Road with a formal ribbon cutting ceremony, speeches, and exclusive tours of the new facility.
-
Leading Institutions Enroll First Alzheimer’s Patients Receiving Amyloid-Targeting Therapy in CARE PMR Study
4/17/2024
Hyperfine, Inc. today announced that the first patients have been enrolled in the CARE PMR (Capturing ARIA Risk Equitably with Portable MR) observational study.
-
Lipella Pharmaceuticals Expands its Advisory Board
4/17/2024
Lipella Pharmaceuticals Inc. today announced the expansion of its Scientific Advisory Board to include oncology expertise.
-
Windtree Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Key Business Updates
4/17/2024
Windtree Therapeutics, Inc. today reported financial results for the fourth quarter and fiscal year ended December 31, 2023 and provided key business updates.
-
NRx Pharmaceuticals, Inc. Announces New Data on NRX-101
4/17/2024
NRx Pharmaceuticals today announced new data that demonstrate that in a rodent model NRX-101 shows no measurable damage to either intestinal or vaginal flora, compared to the significant negative effect caused by drugs such as ciprofloxacin.
-
Celldex Announces Completion of Enrollment in Phase 2 Study of Barzolvolimab in Patients with Chronic Inducible Urticaria
4/17/2024
Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that patient enrollment has been completed in the Company’s Phase 2 clinical study of barzolvolimab for the treatment of the two most common forms of chronic inducible urticaria (CIndU)—cold urticaria (ColdU) and symptomatic dermographism (SD).
-
NRx Pharmaceuticals, Inc. Announces Proposed Underwritten Public Offering of Common Stock - April 17, 2024
4/17/2024
NRx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, announced that it intends to offer to sell shares of its common stock in an underwritten public offering.